Loading…
Loading…
NTHI does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for NTHI and 80,000+ other tickers.
See exactly how NTHI's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for NTHI and 80,000+ other tickers.
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. It develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company was founded in 2008 and is headquartered in Calabasas, CA.
CALABASAS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) (“NeOnc” or the “Company”), a clinical-stage life sciences company focused on the development of treatments for central nervous system cancers, today announced that it has received written feedback from the U.S. Food and Drug Administration (“FDA”) regarding the chemistry, manufacturing and controls (“CMC”) development program for NEO212, the Company's novel temozolomide-perillyl alcohol conjugate.
Three emerging biotechnology companies, Can-Fite (NYSE: CANF), NeOnc (NASDAQ: NTHI), and PMGC (NASDAQ: ELAB) are pursuing a distinct therapeutic strategy
DENVER, June 24, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com ) -- NeOnc Technologies Holdings (NASDAQ: NTHI) is entering one of the most significant periods in its corporate history after securing its second Investigational New Drug (IND) authorization from the United Arab Emirates this month, further expanding international development opportunities for its central nervous system cancer pipeline. The latest authorization from the Department of Health – Abu Dhabi grants IND status to NEO100, NeOnc's lead intranasal therapy candidate for recurrent high-grade gliomas.
Authorization covers all three NEO100 programs across adult Phase 1 through Phase 2, plus pediatric studies Extends NeOnc's UAE footprint beyond NEO212 and complements ongoing U.S. development, where NEO100 holds FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations CALABASAS, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that the Department of Health – Abu Dhabi (DOH) has granted Investigational New Drug (IND) status for NEO100, the Company's lead candidate, an intranasally administered formulation of purified perillyl alcohol designed for non-invasive nose-to-brain delivery.
International Regulatory Validation Has Preceded Several Recent FDA Success Stories, Though Significant Development Risks Remain Houston, Texas--(Newsfile Corp. - June 22, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) recently achieved what many biotechnology companies spend years attempting to secure: international regulatory validation for a novel therapeutic candidate before obtaining later-stage U.S. approvals. The Department of Health - Abu Dhabi's Investigational New Drug (IND) authorization for NEO212 marks the first international regulatory clearance for the company's oral perillyl alcohol-temozolomide conjugate, opening an additional clinical development pathway for a therapy designed to treat aggressive brain cancers, including glioblastoma.